Compile Data Set for Download or QSAR
Report error Found 32 Enz. Inhib. hit(s) with all data for entry = 12639
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716540(US20250034134, Compound I-12A)
Affinity DataIC50: 1.52nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716558(US20250034134, Compound I-28)
Affinity DataIC50: 1.71nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716539(US20250034134, Compound I-12)
Affinity DataIC50: 2.10nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716548(US20250034134, Compound I-25)
Affinity DataIC50: 2.59nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716551(US20250034134, Compound I-20)
Affinity DataIC50: 2.83nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716536(US20250034134, Compound I-3B)
Affinity DataIC50: 3.58nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716533(US20250034134, Compound I-19)
Affinity DataIC50: 3.72nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716550(US20250034134, Compound I-25B)
Affinity DataIC50: 3.78nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716538(US20250034134, Compound I-11)
Affinity DataIC50: 3.80nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716542(US20250034134, Compound I-13)
Affinity DataIC50: 4.03nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716561(US20250034134, Compound I-31)
Affinity DataIC50: 4.10nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716534(US20250034134, Compound I-3)
Affinity DataIC50: 4.20nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716555(US20250034134, Compound I-24)
Affinity DataIC50: 4.23nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716554(US20250034134, Compound I-23)
Affinity DataIC50: 4.26nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716531(US20250034134, Compound I-1)
Affinity DataIC50: 4.30nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716546(US20250034134, Compound I-17)
Affinity DataIC50: 4.5nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716552(US20250034134, Compound I-21)
Affinity DataIC50: 4.95nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716532(US20250034134, Compound I-2)
Affinity DataIC50: 5.15nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716559(US20250034134, Compound I-29)
Affinity DataIC50: 5.30nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716545(US20250034134, Compound I-16)
Affinity DataIC50: 5.40nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716544(US20250034134, Compound I-15)
Affinity DataIC50: 5.70nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716557(US20250034134, Compound I-27)
Affinity DataIC50: 5.70nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716560(US20250034134, Compound I-30)
Affinity DataIC50: 6nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716562(US20250034134, Compound I-32)
Affinity DataIC50: 6.30nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716541(US20250034134, Compound I-12B)
Affinity DataIC50: 7.42nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716543(US20250034134, Compound I-14)
Affinity DataIC50: 8.60nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716537(US20250034134, Compound I-9)
Affinity DataIC50: 9.51nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716556(US20250034134, Compound I-26)
Affinity DataIC50: 9.90nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716553(US20250034134, Compound I-22)
Affinity DataIC50: 10.2nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716535(US20250034134, Compound I-3A)
Affinity DataIC50: 12.2nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716549(US20250034134, Compound I-25A)
Affinity DataIC50: 15.8nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Wuhan Humanwell Innovative Drug Research and Development Center

US Patent
LigandPNGBDBM716547(US20250034134, Compound I-18)
Affinity DataIC50: 20nMAssay Description:15-PGDH (R&D Systems, Cat. No.: 5660-DH-010) was prepared to twice the final concentration, i.e., 30 nM, using Assay Buffer (50 mM Tris-HCl, pH 7.5, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent